Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.45 and traded as low as $3.38. Cryo-Cell International shares last traded at $3.48, with a volume of 7,647 shares changing hands.

Cryo-Cell International Trading Down 2.8%

The business’s fifty day moving average price is $3.52 and its 200 day moving average price is $3.45. The company has a market capitalization of $28.05 million, a P/E ratio of -11.60 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its earnings results on Wednesday, July 15th. The company reported $0.07 earnings per share for the quarter. The business had revenue of $7.78 million during the quarter.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International at the end of the most recent quarter. Institutional investors own 10.44% of the company’s stock.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.